Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;144(1):109003.
doi: 10.1016/j.ymgme.2024.109003. Epub 2024 Dec 22.

Characterization of gallbladder disease in metachromatic leukodystrophy across the lifespan

Affiliations

Characterization of gallbladder disease in metachromatic leukodystrophy across the lifespan

Sylvia Mutua et al. Mol Genet Metab. 2025 Jan.

Abstract

Metachromatic leukodystrophy (MLD) is a progressive demyelinating disorder resulting from the toxic accumulation of sulfatides. The stereotyped neurodegeneration of MLD is well understood, and cases are categorized into subtypes by age at neurologic onset: late infantile (LI), juvenile (J), and adult. The systemic burden of disease, such as gallbladder involvement, however, is less well characterized. It is important to understand the longitudinal trajectory of gallbladder complications in MLD and its relationship with neurologic progression as this has the potential to identify cases of active disease before neurologic onset. Additionally, as newborn screening is established in MLD, it will inform clinical care during the presymptomatic period. To address this knowledge gap, we leveraged a retrospective natural history study of MLD and published cases in the medical literature. Medical records from subjects consented to a natural history study were used to collect information of disease course, including gallbladder abnormality. Neurologic function was retrospectively assessed using the gross motor function classification scale (GMFC-MLD). Additionally, a comprehensive review identified published cases of MLD with subject-level information around gallbladder disease. Data was summarized using descriptive statistics, Fisher's exact test for significance, and survival analysis with log rank test. The natural history cohort includes 40 subjects with gallbladder reports (imaging or pathology). The first gallbladder evaluation occurred after neurologic onset in 35/40 cases. Gallbladder abnormalities were noted in 36 subjects, often within the initial evaluation (97.2 %). There was no difference in the time to first gallbladder abnormality (log rank: p = 0.4170) and risk of polyps or higher (log rank: p = 0.6414) between the LI- and non-LI subtypes. The level of gallbladder involvement does not correlate with GMFC-MLD score (Fisher's exact: p = 0.321). A review of the literature identified 87 additional cases of MLD with mention of gallbladder status across 40 published studies. Gallbladder involvement was noted in 74 cases and occurred at similar rates across subtypes (X2 = 4.68, p = 0.7925). Overall, the study showed a high prevalence of gallbladder complications in MLD. Gallbladder abnormalities were commonly found at first evaluation, even in pre- or early symptomatic disease. Since gallbladder disease has the potential to progress to malignancy, this supports the integration of regular gallbladder monitoring as clinical care and its potential as a predictive biomarker supporting disease onset.

Keywords: Gallbladder; Gallbladder screening; Longitudinal natural history study; Metachromatic leukodystrophy.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest AV receives grant and in-kind support for research from Eli Lilly, Sana Biotechnology, Boehringer Ingelheim, Affynia, Sanofi, Synaptix Bio, Takeda, Illumina, Biogen, Myrtelle, Homology, Ionis, Passage Bio, and Orchard Therapeutics. AV serves on the scientific advisory boards of the European Leukodystrophy Association and the United Leukodystrophy Foundation, as well as in an unpaid capacity for Takeda, Ionis, Biogen and Illumina.

Similar articles

References

    1. Farah MH, Dali C, Groeschel S, Moldovan M, Whiteman DAH, Malanga CJ, Krägeloh-Mann I, Li J, Barton N, Krarup C, Effects of sulfatide on peripheral nerves in metachromatic leukodystrophy, Ann. Clin. Transl. Neurol 11 (2) (2024) 328–341. Epub 20231226, 10.1002/acn3.51954. - DOI - PMC - PubMed
    1. Fumagalli F, Zambon AA, Rancoita PMV, Baldoli C, Canale S, Spiga I, Medaglini S, Penati R, Facchini M, Ciotti F, Sarzana M, Lorioli L, Cesani M, Natali Sora MG, Del Carro U, Cugnata F, Antonioli G, Recupero S, Calbi V, Di Serio C, Aiuti A, Biffi A, Sessa M, Metachromatic leukodystrophy: A single-center longitudinal study of 45 patients, J. Inherit. Metab. Dis. 44 (5) (2021) 1151–1164. Epub 20210504, 10.1002/jimd.12388. - DOI - PubMed
    1. Santhanakumaran V, Groeschel S, Harzer K, Kehrer C, Elgün S, Beck-Wödl S, Hengel H, Schöls L, Haack TB, Krägeloh-Mann I, Laugwitz L, Predicting clinical phenotypes of metachromatic leukodystrophy based on the arylsulfatase A activity and the ARSA genotype? - Chances and challenges, Mol. Genet. Metab. 137 (3) (2022) 273–282. Epub 20220930, 10.1016/j.ymgme.2022.09.009. - DOI - PubMed
    1. Kehrer C, Blumenstock G, Gieselmann V, Krageloh-Mann I, The natural course of gross motor deterioration in metachromatic leukodystrophy, Dev. Med. Child Neurol 53 (9) (2011) 850–855. Epub 2011/06/29, 10.1111/j.1469-8749.2011.04028.x. - DOI - PubMed
    1. Kehrer C, Blumenstock G, Raabe C, Krageloh-Mann I, Development and reliability of a classification system for gross motor function in children with metachromatic leucodystrophy, Dev. Med. Child Neurol 53 (2) (2011) 156–160. Epub 2010/11/20, 10.1111/j.1469-8749.2010.03821.x. - DOI - PubMed

MeSH terms

LinkOut - more resources